# DESCRIPTION

## TECHNICAL FIELD

- introduce technical field of compositions and methods for treating seizure-induced death

## BACKGROUND

- define sudden unexpected death in epilepsy
- discuss prevalence of SUDEP
- describe rodent models of SUDEP
- summarize limitations of existing models

## SUMMARY

- introduce germline modified animals
- describe gain-of-function SCN8A mutation
- outline methods for inducing audiogenic seizures
- describe methods for treating seizure-induced death
- introduce alpha-1 adrenergic receptor activators
- outline methods for identifying compounds
- describe methods for preventing SUDEP
- outline methods for preventing death in subjects with gain-of-function mutations
- describe methods for preventing tonic seizure-induced death
- outline methods for preventing epileptic seizure-induced death
- introduce mechanical ventilation
- describe administration of alpha-1 adrenergic receptor activators
- outline methods for providing mechanical ventilation
- describe composition of alpha-1 adrenergic receptor activators
- outline routes of administration
- describe human subjects
- introduce injectable compositions
- describe pen delivery devices
- outline intraperitoneal administration
- describe intramuscular administration
- outline intravenous administration
- describe intranasal administration
- introduce compositions for treating seizure-induced death
- describe methods for treating seizure-induced death
- outline methods for preventing SUDEP
- describe methods for preventing death in subjects with gain-of-function mutations
- outline methods for preventing tonic seizure-induced death
- describe methods for preventing epileptic seizure-induced death
- introduce compositions for preventing SUDEP
- describe methods for preventing SUDEP

## DETAILED DESCRIPTION

- introduce transgenic mouse model
- describe limitations of current models
- demonstrate evoked seizures in D/+ mice
- summarize key findings

### I. General Considerations

- motivate SUDEP research
- describe current understanding of SUDEP
- introduce audiogenic seizure model

### II. Definitions

- define articles "a" and "an"
- define "about"
- define "comprising"
- explain "comprising" as open-ended
- define "consisting of"
- explain "consisting of" as exclusive
- define "consisting essentially of"
- explain "consisting essentially of" as limiting
- relate "comprising", "consisting essentially of", and "consisting of"
- define "administration of" and "administering"
- define "adult"
- define "agent"
- define "agonist"
- define "antagonist"
- define "amino acid"
- explain amino acid structure
- classify amino acids
- define "basic" or "positively charged" amino acid
- define "antisense oligonucleotide" or "antisense nucleic acid"
- define "autologous"
- define "control"
- define "test"
- define "pathoindicative"
- define "normally comprises"
- define "compound"
- define "delivery vehicle"
- define "derivative"
- define "detect" and "determine"
- define "disease"
- define "disorder"
- define "effective amount"
- define "ingredient"
- define "inhibit"
- define "inhibitor"
- define "injecting or applying"
- define "injury"
- define "instructional material"
- define "isolate" and "select"
- define linker
- define modulate
- define nucleic acid
- define nucleic acid construct
- define nucleotide sequence encoding an amino acid sequence
- define oligonucleotide
- define operably linked
- define parenteral administration
- define pharmaceutical composition
- define pharmaceutically-acceptable carrier
- define physiologically acceptable ester or salt
- define plurality
- define polynucleotide
- define polypeptide
- define prevent
- define primer
- define prophylactic treatment
- define protein
- define protein pathway
- define purified
- define recombinant polynucleotide
- define recombinant host cell
- define recombinant polypeptide
- define regulate
- define regulatory elements
- define reversibly implantable device
- define sample
- define significant detectable level
- define standard
- define stimulate
- define subject
- define subject in need thereof
- define substantially pure
- define symptom
- define therapeutic treatment
- define therapeutically effective amount
- define tissue
- define topical application
- define transgene

### III. Animal Models of SCN8A Epilepsy

- introduce germline modified animals
- describe production of transgenic mouse
- list exemplary gain-of-function SCN8A mutations
- describe modification of codons using TALEN or Crispr/Cas system

### IV. Methods for Inducing Audiogenic Seizures and Seizure-Induced Death

- introduce methods for inducing audiogenic seizures and seizure-induced death
- describe characteristics of patients with SCN8A epilepsy
- relate mouse models to human SCN8A epilepsy
- describe alpha-1 receptor stimulation and mechanical ventilation
- propose use of alpha 1 adrenergic receptor agonists to prevent SUDEP
- describe audiogenic stimuli for inducing seizures and seizure-induced death
- list exemplary audiogenic stimuli
- describe duration and intensity of audiogenic stimuli
- relate to human SCN8A epilepsy mutations

### VI. Compositions for Preventing Seizure-Induced Death

- introduce alpha-1 adrenergic receptor activators
- list exemplary alpha-1 adrenergic receptor activators
- describe utility of phenylephrine as a potential SUDEP therapeutic intervention
- propose use of phenylephrine as an interventional medication
- describe potential closed-loop seizure-detection and medication delivery approaches
- relate to human epilepsy patients
- describe applicability to other epilepsy etiologies
- list SUDEP mouse models
- describe prevention of death by enhancement of the noradrenergic system
- relate to Lennox-Gastaut Syndrome
- introduce formulations
- describe pharmaceutical formulations
- list ingredients of formulations
- describe sterile pyrogen-free aqueous and non-aqueous solutions
- introduce dosages
- define effective dose
- describe factors affecting dosage levels
- propose starting doses and adjusting as needed
- introduce routes of administration
- list routes of administration
- describe regionalized delivery or accumulation
- propose use of pen delivery devices

### VII. Methods for Preventing Seizure-Induced Death

- introduce methods for treating and/or preventing death associated with seizures
- define alpha-1 adrenergic receptor activator
- specify administration timing of alpha-1 adrenergic receptor activator
- describe mechanical ventilation
- introduce SUDEP
- define gain-of-function mutation in SCN8A gene product
- list exemplary gain-of-function SCN8A mutations
- describe methods for preventing or reducing SUDEP
- define preventing or reducing the incidence of SUDEP
- specify administration timing of alpha-1 adrenergic receptor activator for SUDEP
- describe mechanical ventilation for SUDEP
- introduce methods for preventing and/or reducing the risk of death in subjects with SCN8A gain-of-function mutations
- define preventing and/or reducing the risk of death
- describe methods for preventing and/or reducing the risk of death in subjects with SCN8A gain-of-function mutations
- list SCN8A gain-of-function mutations
- introduce methods for preventing or reducing the risk of death associated with tonic seizures
- describe methods for preventing or reducing the risk of death associated with tonic seizures
- introduce methods for preventing or reducing the risk of death associated with epileptic seizures
- describe methods for preventing or reducing the risk of death associated with epileptic seizures
- specify subject type

## EXAMPLES

- introduce examples of patent application

### Materials and Methods for the Examples

- describe mouse housing and maintenance
- describe genotyping of transgenic mice
- describe audiogenic seizure assessment
- describe intensity-dependence of audiogenic seizures
- describe auditory brainstem responses
- describe surgical preparation for ECoG/ECG headsets
- describe recording of ECoG, ECG, and breathing for spontaneous seizures
- describe recording of ECoG, ECG, and breathing for audiogenic seizures
- describe breathing and heart rate detection
- describe mechanical ventilation
- describe adrenergic receptor pharmacology
- describe statistical analysis
- describe experimental setup for audiogenic seizures
- describe experimental setup for spontaneous seizures
- describe data analysis for audiogenic seizures
- describe data analysis for spontaneous seizures
- describe comparison of audiogenic and spontaneous seizures
- describe characterization of audiogenic seizure behavior
- describe intensity-sensitivity of audiogenic seizures
- describe hearing sensitivity in D/+ mice
- describe audiogenic seizure-induced death
- describe mechanical ventilation rescue
- describe adrenergic receptor function in breathing recovery

### Example 1

- characterize audiogenic seizure behavior in D/+ mice
- describe age-dependent susceptibility to audiogenic seizures
- describe stereotyped seizure behaviors
- describe latency to seizure and seizure phase durations
- describe intensity-sensitivity of audiogenic seizures
- describe hearing sensitivity in D/+ mice

### Example 2

- describe similarities between audiogenic and spontaneous seizures
- describe differences in ictal and postictal breathing and heart rate

### Example 3

- describe audiogenic seizure-induced death in P20-21 D/+ mice
- describe breathing activity during terminal seizures
- describe mechanical ventilation rescue of seizure-induced death

### Example 4

- describe exogenous alpha-1 adrenergic receptor stimulation
- describe breathing recovery and survival in P20-21 D/+ mice
- describe selective alpha-1 receptor agonism

### Example 5

- describe endogenous adrenergic receptor function in breathing recovery
- describe necessity of adrenergic receptor function for survival

### Example 6

- describe prevention of seizure-induced death with mechanical ventilation
- describe adrenergic receptor function in breathing recovery
- describe mechanical ventilation rescue in absence of adrenergic receptor function

### Example 7

- investigate apnea during audiogenic seizures
- analyze effect of adrenergic receptor activity on survival

### Discussion of the Examples

- discuss age-dependent response to audiogenic seizure tests
- describe changes in heart rate during seizures
- discuss technical difficulties in recording cardiac activity
- interpret effect of i.p. phenylephrine on CNS
- speculate on blood pressure-maintaining effect of peripheral norepinephrine release
- note minimal effect of peripheral alpha-1 stimulation on heart
- compare male and female D/+ mice in seizure behavior progressions
- discuss effect of epinephrine and norepinephrine on alpha receptors
- note effect of selective beta-2 agonists on bronchodilation
- discuss effect of phenylephrine on breathing recovery and survival
- interpret results to indicate role for alpha-1 receptors in seizure survival
- discuss anomaly of fatal audiogenic seizures in young but not old mice
- discuss possibility of cardiac dysfunction as contributor to seizure-induced death
- describe respiration in P20-21 D/+ mice
- discuss challenges of implanting ECoG and ECG leads in P20-21 D/+ mice
- discuss possibility of cardiac dysfunction as contributor to seizure-induced death
- discuss apparent anomaly of fatal audiogenic seizures in young but not old mice
- discuss context of audiogenic seizures
- discuss acclimation period for behavioral experiments
- present finding that mice expressing patient-derived N1768D SCN8A mutation had audiogenic seizures
- discuss blockade of adrenergic receptors resulting in seizure-induced death
- discuss activation of alpha-1 adrenergic receptors rescuing seizure-induced death
- discuss Scn8a mutant mice having audiogenic seizures
- describe SCN8A encephalopathy as severe genetic epilepsy syndrome
- discuss aberrant neuronal excitability in various cortical neurons
- discuss additional regions impacted by SCN8A mutations
- discuss risk of death from audiogenic seizures in D/+ mice
- discuss age-dependent differences in seizure phenotype and risk for sudden death
- discuss gain of function mutations in SCN8A leading to altered wiring of auditory neural circuits
- discuss alpha-1 adrenergic receptor function at P20-21
- discuss low mortality of audiogenic seizures in adult D/+ mice
- discuss likelihood of death from any single audiogenic versus spontaneous seizure
- discuss developmentally-determined alpha-1 adrenergic signaling relating to seizure-induced sudden death
- discuss impaired hearing in D/+ mice
- discuss importance of hearing impairment and seizures in SCN8A encephalopathy patients
- discuss present model allowing for examination of cascade of events leading to fatal or non-fatal seizures
- discuss differences in relative timing of ECoG ictal activity and onset of tonic phase
- discuss respiratory arrest contributing to seizure-induced death
- discuss increasing evidence that respiratory arrest is primary cause of death in SUDEP
- discuss data obtained from mouse models of SUDEP supporting notion of respiratory failure
- discuss breathing dysfunction in seizures induced under urethane anesthesia
- discuss tonic phase apnea and failure of breathing recovery
- discuss adrenergic signaling and seizure survival
- discuss mechanisms of seizure-induced death and potential therapeutic interventions

